AVTE20270115P5
AVTE Jan 15 2027 5.00 Put (AVTE270115P00005000)
option OPRA

aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.